1 / 16

FDA Presentation ODAC Meeting July 24 2007

FDA Presentation ODAC Meeting July 24 2007. NDA 22042 Applicant: Eli Lilly Evista ® (Raloxifene Hydrochloride). Evista ® Review Team. Primary Reviewers Team Leaders Medical Patricia Cortazar John R Johnson Bhupinder S Mann Statistical Kun He Raji Sridhara

irish
Download Presentation

FDA Presentation ODAC Meeting July 24 2007

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. FDA PresentationODAC Meeting July 24 2007 NDA 22042 Applicant: Eli Lilly Evista® (Raloxifene Hydrochloride)

  2. Evista® Review Team Primary Reviewers Team Leaders Medical Patricia Cortazar John R Johnson Bhupinder S Mann Statistical Kun He Raji Sridhara Clinical Pharmacology Julie Bullock Brian Booth CMC Sarah Pope Ravi Harapanhalli Project Manager Patricia Garvey DSI Lauren Iacono-ConnorsLeslie Ball

  3. Raloxifene Proposed New Indication:Women with Osteoporosis • “The reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis” • Supporting trials: • RUTH, MORE and CORE

  4. Raloxifene Proposed New Indication:Women at High Risk for Breast Cancer • “The reduction in risk of invasive breast cancer in postmenopausal women at high risk for breast cancer” • Supporting trial: • STAR

  5. Issues to Consider before Approval • Safety and efficacy of raloxifene • Clinical Benefit: • Reduction in the incidence of invasive breast cancer • Risks: • Adverse events associated with raloxifene exposure • Deep vein thrombosis • Pulmonary embolism • Death due to stroke

  6. Approved Drug: Nolvadex (Tamoxifen Citrate) • “NOLVADEX is indicated to reduce the incidence of breast cancer in women at high risk for breast cancer.” • NSABP BCPT P-1 Eligibility: • Age 35 to 59 years with projected 5-year risk of invasive breast cancer ≥ 1.66% • Age ≥ 60 years • Lobular Carcinoma in situ

  7. Raloxifene: Placebo-controlled Trials

  8. Raloxifene Placebo-controlled Trials: Treatment Arms & Exclusion Criteria

  9. RUTH: Invasive Breast Cancers • Invasive breast cancers: • Raloxifene 40 (N = 5,044) • IR per 1,000 person-years 1.50 • Placebo 70 (N = 5,057) • IR per 1,000 person-years 2.66 • Absolute risk difference 1.16 • Breast cancers diagnosed at stage ≤ II A • Placebo 92% • Raloxifene 83% IR: Incidence Rate

  10. RUTH: Comparison of Safety and Efficacy

  11. MORE: Invasive Breast Cancers • Invasive breast cancers: • Raloxifene 11 (N = 2,576) • IR per 1,000 person-years 1.26 • Placebo 38 (N = 2,557) • IR per 1000 person-years 4.36 • Absolute risk difference 3.10 • Breast cancers diagnosed at stage ≤ II A • Placebo 96% • Raloxifene 90%

  12. MORE: Comparison of Safety and Efficacy

  13. CORE: Invasive Breast Cancers • Invasive breast cancers: • Raloxifene 19 (N = 2,716) • IR per 1,000 person-years 2.43 • Placebo 20 (N = 1,274) • IR per 1000 person-years 5.41 • Absolute risk difference 2.98 • Breast cancers diagnosed at stage ≤ II A • Placebo arm 94% • Raloxifene arm 90%

  14. CORE: Comparison of Safety and Efficacy

  15. Summary of Benefits vs. RisksRaloxifene Placebo-controlled Trials • RUTH:Benefit equals Risk • Benefit: ARR of1.16 IBC per 1,000 P-Y and osteoporosis prevention and treatment • Risk: equal increase in thromboembolic AEs IR • MORE: Benefit more than Risk • Benefit: ARR of3.10 IBC per 1,000 P-Y and osteoporosis prevention and treatment • Risk: smaller increase in thromboembolic AEs IR • CORE: Risk outweighs Benefit • Benefit: ARR of2.98 IBC per 1,000 P-Y and osteoporosis prevention and treatment • Risk: larger increase in thromboembolic AEs IR ARR: absolute risk reduction, IBC: invasive breast cancer, P-Y: person-years, AE: adverse events, IR: incidence rate

  16. Raloxifene: Risk vs. BenefitRaloxifene Placebo-controlled Trials • Reduced risk of invasive breast cancers • Variability of raloxifene effect size: • Number of women needed to treat (NNT) for one year to prevent one invasive breast cancer: • RUTH 862 (Women with ≥4 CV risk score) • MORE 323 (Women with osteoporosis) • CORE 335 (Women with osteoporosis) • NSABP P-1 300 (Women ≥35 y old, at high risk) • Increased risk of thromboembolic adverse events • Comparison of Risk vs.Benefit: • Reduction in invasive breast cancer incidence and osteoporosis prevention and treatment benefit vs. increased risk of thromboembolic AEs

More Related